Hypertension Drug Market is Anticipated to Increase at a Stable CAGR over the Forecast Period (2023 to 2029)

The global hypertension drug market is anticipated to grow at a significant CAGR during the forecast period. Hypertension is a common condition which occurred due to the long-term force of the blood against the artery walls. Additionally, it is marked by high blood pressure and can also cause health problems, such as heart disease. The major factor driving the demand for the global hypertension drug market during the forecast period is the increasing prevalence of hypertension across the globe. 

According to the Center for Disease Control and Prevention, nearly half of adults or 47%, or 116 million have hypertension which is defined as a systolic blood pressure greater than 130 mmHg or diastolic blood pressure greater than 80 mmHg or are taking medication for hypertension in the US. Additionally, about 1 in 4 adults (24%) with hypertension have their condition under control and about half of the adults or 45% or 37 million with uncontrolled hypertension have a blood pressure of 140/90 mmHg or higher in the US. Furthermore, about 34 million adults are recommended to take medication and about two out of three of this group or 19 million have a blood pressure of 140/90 mmHg or higher. Hence, the increasing prevalence of hypertension is driving the demand for hypertension drugs which in turn is driving the growth of the market.

Some major players in the market include GlaxoSmithKline plc, Sanofi S.A., and Novartis International among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in December 2021, Dr Reddy's Laboratories announced the launch of Valsartan tablets which is the therapeutic equivalent of Diovan in the US market, It is used for the treatment of high blood pressure and heart failure.

To Request a Sample of our Report on Hypertension Drug Market:  https://www.omrglobal.com/request-sample/hypertension-drug-market

Market Coverage

The market number available for - 2022-2030
Base year- 2022
Forecast period- 2023-2030

Segment Covered- 

By Drug Class
By Distribution Channel

Regions Covered-

North America
Europe
Asia-Pacific
Rest of the World

Competitive Landscape- GlaxoSmithKline plc, Sanofi S.A., and Novartis International among others.

Hypertension Drug Market Report by Segment

By Drug Class 

Diuretics
ACE Inhibitors
Calcium Channel Blockers
Vasodilators
Beta-adrenergic Blockers
Others

By Distribution Channel 

Retail Pharmacy
Hospital Pharmacy
E-commerce

A full Report of Hypertension Drug Market is Available @ https://www.omrglobal.com/industry-reports/hypertension-drug-market

Hypertension Drug Market Report by Region

North America

United States
Canada

Europe

UK
Germany
Spain
France
Italy
Rest of Europe

Asia-Pacific

India
China
Japan
South Korea
Rest of APAC

Rest of the World

Latin America 
Middle East & Africa

Reasons to buy from us -

We cover more than 15 major industries, further segmented into more than 90 sectors.
More than 120 countries are for analysis.
Over 100+ paid data sources mined for investigation.
Our expert research analysts answer all your questions before and after purchasing your report.

 

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no:  +91 7803040404

About Orion Market Research 
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.